Business Description
Jade Biosciences Inc
NAICS : 541714
SIC : 2833
ISIN : US0080642061
Total Employee Number:
55Description
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 458.46 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 12.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 57.82 | |||||
9-Day RSI | 58.55 | |||||
14-Day RSI | 57.01 | |||||
3-1 Month Momentum % | -29.02 | |||||
6-1 Month Momentum % | 5.65 | |||||
12-1 Month Momentum % | 76.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 14.29 | |||||
Quick Ratio | 14.29 | |||||
Cash Ratio | 13.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -51.34 | |||||
ROA % | -47.32 | |||||
ROIC % | -2048.34 | |||||
ROC (Joel Greenblatt) % | -14915.21 | |||||
ROCE % | -52.76 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.41 | |||||
Price-to-Tangible-Book | 3.41 | |||||
EV-to-EBIT | -7 | |||||
EV-to-EBITDA | -7.01 | |||||
EV-to-FCF | -9.36 | |||||
| Price-to-Net-Current-Asset-Value | 3.42 | |||||
| Price-to-Net-Cash | 3.51 | |||||
Earnings Yield (Greenblatt) % | -14.29 | |||||
FCF Yield % | -8.02 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:JBIO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Jade Biosciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.557 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 88.43 | ||
| 14-Day RSI | 57.01 | ||
| 14-Day ATR ($) | 1.72342 | ||
| 20-Day SMA ($) | 20.9115 | ||
| 12-1 Month Momentum % | 76.28 | ||
| 52-Week Range ($) | 6.67 - 28 | ||
| Shares Outstanding (Mil) | 60.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jade Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Jade Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 119 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 27 days | ||
| General meeting for 2025 | 2026-06-09 12:00 | 14.98 (-12.60%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 25.13 (-1.49%) | ||
| Leerink Global Healthcare Conference | 2026-03-11 08:40 | 14.48 (+0.56%) | ||
| Jefferies Biotech on the Beach Summit | 2026-03-10 | 14.43 (-0.07%) | ||
| Annual report for 2025 | 2026-03-06 | 13.88 (+0.07%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-06 | 13.88 (+0.07%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 10:30 | 14.83 (+4.29%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-26 13:20 | 14.50 (+3.79%) |
Show
Entries
Jade Biosciences Inc Frequently Asked Questions
What is Jade Biosciences Inc(JBIO)'s stock price today?
The current price of JBIO is $20.48. The 52 week high of JBIO is $28.00 and 52 week low is $6.67.
When is next earnings date of Jade Biosciences Inc(JBIO)?
The next earnings date of Jade Biosciences Inc(JBIO) is 2026-08-13 Est..
Does Jade Biosciences Inc(JBIO) pay dividends? If so, how much?
Jade Biosciences Inc(JBIO) does not pay dividend.
Guru Commentaries on NAS:JBIO
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Jade Biosciences Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers